This company has been marked as potentially delisted and may not be actively trading.

Alimera Sciences (ALIM) Competitors

ALIM vs. ABCL, PHAR, MLTX, URGN, and DBVT

Should you be buying Alimera Sciences stock or one of its competitors? The main competitors of Alimera Sciences include AbCellera Biologics (ABCL), Pharming Group (PHAR), MoonLake Immunotherapeutics (MLTX), Urogen Pharma (URGN), and DBV Technologies (DBVT). These companies are all part of the "pharmaceutical products" industry.

How does Alimera Sciences compare to AbCellera Biologics?

Alimera Sciences (NASDAQ:ALIM) and AbCellera Biologics (NASDAQ:ABCL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

99.8% of Alimera Sciences shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 31.4% of Alimera Sciences shares are owned by insiders. Comparatively, 28.9% of AbCellera Biologics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Alimera Sciences has higher revenue and earnings than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Alimera Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alimera Sciences	$99.68M	2.91	-$20.13M	-$1.57	N/A
AbCellera Biologics	$75.13M	21.29	-$146.41M	-$0.49	N/A

In the previous week, AbCellera Biologics had 9 more articles in the media than Alimera Sciences. MarketBeat recorded 9 mentions for AbCellera Biologics and 0 mentions for Alimera Sciences. AbCellera Biologics' average media sentiment score of 0.57 beat Alimera Sciences' score of 0.00 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company	Overall Sentiment
Alimera Sciences	Neutral
AbCellera Biologics	Positive

Alimera Sciences has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500.

Alimera Sciences has a net margin of -14.74% compared to AbCellera Biologics' net margin of -198.37%. AbCellera Biologics' return on equity of -15.05% beat Alimera Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alimera Sciences	-14.74%	-33.70%	-9.63%
AbCellera Biologics	-198.37%	-15.05%	-10.92%

AbCellera Biologics has a consensus target price of $8.17, indicating a potential upside of 55.85%. Given AbCellera Biologics' stronger consensus rating and higher possible upside, analysts plainly believe AbCellera Biologics is more favorable than Alimera Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alimera Sciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

AbCellera Biologics beats Alimera Sciences on 9 of the 17 factors compared between the two stocks.

How does Alimera Sciences compare to Pharming Group?

Alimera Sciences (NASDAQ:ALIM) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

99.8% of Alimera Sciences shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 31.4% of Alimera Sciences shares are owned by insiders. Comparatively, 2.1% of Pharming Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Pharming Group has higher revenue and earnings than Alimera Sciences. Alimera Sciences is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alimera Sciences	$99.68M	2.91	-$20.13M	-$1.57	N/A
Pharming Group	$376.13M	2.44	$2.85M	$0.01	1,298.00

In the previous week, Pharming Group had 14 more articles in the media than Alimera Sciences. MarketBeat recorded 14 mentions for Pharming Group and 0 mentions for Alimera Sciences. Pharming Group's average media sentiment score of 0.06 beat Alimera Sciences' score of 0.00 indicating that Pharming Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Alimera Sciences	Neutral
Pharming Group	Neutral

Alimera Sciences has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Comparatively, Pharming Group has a beta of 0.04, suggesting that its share price is 96% less volatile than the S&P 500.

Pharming Group has a net margin of 3.30% compared to Alimera Sciences' net margin of -14.74%. Pharming Group's return on equity of 4.68% beat Alimera Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alimera Sciences	-14.74%	-33.70%	-9.63%
Pharming Group	3.30%	4.68%	2.57%

Pharming Group has a consensus target price of $38.33, indicating a potential upside of 195.33%. Given Pharming Group's stronger consensus rating and higher possible upside, analysts plainly believe Pharming Group is more favorable than Alimera Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alimera Sciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Pharming Group	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Pharming Group beats Alimera Sciences on 12 of the 16 factors compared between the two stocks.

How does Alimera Sciences compare to MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Alimera Sciences (NASDAQ:ALIM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

MoonLake Immunotherapeutics has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, Alimera Sciences has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500.

Alimera Sciences has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Alimera Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.52	N/A
Alimera Sciences	$99.68M	2.91	-$20.13M	-$1.57	N/A

In the previous week, MoonLake Immunotherapeutics had 3 more articles in the media than Alimera Sciences. MarketBeat recorded 3 mentions for MoonLake Immunotherapeutics and 0 mentions for Alimera Sciences. MoonLake Immunotherapeutics' average media sentiment score of 0.73 beat Alimera Sciences' score of 0.00 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
MoonLake Immunotherapeutics	Positive
Alimera Sciences	Neutral

MoonLake Immunotherapeutics presently has a consensus target price of $23.08, indicating a potential upside of 35.27%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe MoonLake Immunotherapeutics is more favorable than Alimera Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.38
Alimera Sciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. Comparatively, 99.8% of Alimera Sciences shares are owned by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are owned by company insiders. Comparatively, 31.4% of Alimera Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

MoonLake Immunotherapeutics has a net margin of 0.00% compared to Alimera Sciences' net margin of -14.74%. Alimera Sciences' return on equity of -33.70% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-66.56%	-50.23%
Alimera Sciences	-14.74%	-33.70%	-9.63%

Summary

Alimera Sciences beats MoonLake Immunotherapeutics on 9 of the 15 factors compared between the two stocks.

How does Alimera Sciences compare to Urogen Pharma?

Alimera Sciences (NASDAQ:ALIM) and Urogen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

Urogen Pharma has a consensus target price of $35.25, indicating a potential upside of 19.90%. Given Urogen Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Urogen Pharma is more favorable than Alimera Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alimera Sciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Alimera Sciences has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Comparatively, Urogen Pharma has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500.

99.8% of Alimera Sciences shares are held by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are held by institutional investors. 31.4% of Alimera Sciences shares are held by insiders. Comparatively, 4.7% of Urogen Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Alimera Sciences has a net margin of -14.74% compared to Urogen Pharma's net margin of -94.83%. Urogen Pharma's return on equity of 0.00% beat Alimera Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alimera Sciences	-14.74%	-33.70%	-9.63%
Urogen Pharma	-94.83%	N/A	-62.85%

Alimera Sciences has higher earnings, but lower revenue than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Alimera Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alimera Sciences	$99.68M	2.91	-$20.13M	-$1.57	N/A
Urogen Pharma	$109.79M	13.05	-$153.49M	-$2.75	N/A

In the previous week, Urogen Pharma had 16 more articles in the media than Alimera Sciences. MarketBeat recorded 16 mentions for Urogen Pharma and 0 mentions for Alimera Sciences. Urogen Pharma's average media sentiment score of 0.37 beat Alimera Sciences' score of 0.00 indicating that Urogen Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Alimera Sciences	Neutral
Urogen Pharma	Neutral

Summary

Urogen Pharma beats Alimera Sciences on 10 of the 17 factors compared between the two stocks.

How does Alimera Sciences compare to DBV Technologies?

Alimera Sciences (NASDAQ:ALIM) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

99.8% of Alimera Sciences shares are held by institutional investors. Comparatively, 71.7% of DBV Technologies shares are held by institutional investors. 31.4% of Alimera Sciences shares are held by insiders. Comparatively, 1.4% of DBV Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, DBV Technologies had 13 more articles in the media than Alimera Sciences. MarketBeat recorded 13 mentions for DBV Technologies and 0 mentions for Alimera Sciences. DBV Technologies' average media sentiment score of 0.23 beat Alimera Sciences' score of 0.00 indicating that DBV Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Alimera Sciences	Neutral
DBV Technologies	Neutral

Alimera Sciences has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Comparatively, DBV Technologies has a beta of -0.96, suggesting that its share price is 196% less volatile than the S&P 500.

DBV Technologies has a consensus target price of $40.25, indicating a potential upside of 104.00%. Given DBV Technologies' stronger consensus rating and higher probable upside, analysts plainly believe DBV Technologies is more favorable than Alimera Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alimera Sciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
DBV Technologies	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.67

Alimera Sciences has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Alimera Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alimera Sciences	$99.68M	2.91	-$20.13M	-$1.57	N/A
DBV Technologies	$5.64M	194.75	-$146.95M	-$4.46	N/A

Alimera Sciences has a net margin of -14.74% compared to DBV Technologies' net margin of -2,895.37%. Alimera Sciences' return on equity of -33.70% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alimera Sciences	-14.74%	-33.70%	-9.63%
DBV Technologies	-2,895.37%	-129.88%	-88.84%

Summary

Alimera Sciences beats DBV Technologies on 10 of the 17 factors compared between the two stocks.

Get Alimera Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALIM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALIM vs. The Competition

Export

Metric	Alimera Sciences	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$290.24M	$904.51M	$6.25B	$12.13B
Dividend Yield	N/A	4.84%	2.78%	5.20%
P/E Ratio	-3.53	1.56	20.88	25.39
Price / Sales	2.91	121.17	533.01	77.05
Price / Cash	N/A	20.07	43.29	53.47
Price / Book	6.30	7.71	9.98	6.81
Net Income	-$20.13M	-$5.06M	$3.54B	$332.87M

Alimera Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALIM Alimera Sciences	N/A	$5.54 flat	N/A	N/A	$290.24M	$99.68M	N/A	150
ABCL AbCellera Biologics	2.9167 of 5 stars	$3.82 -8.2%	$8.40 +119.9%	+139.8%	$1.16B	$75.13M	N/A	500	Upcoming Earnings Analyst Forecast High Trading Volume
PHAR Pharming Group	4.0721 of 5 stars	$16.38 -0.2%	$38.33 +134.0%	+32.3%	$1.16B	$376.13M	1,638.00	280	News Coverage Earnings Report Gap Up
MLTX MoonLake Immunotherapeutics	3.386 of 5 stars	$16.11 -3.3%	$23.08 +43.2%	-54.3%	$1.16B	N/A	N/A	2	Upcoming Earnings
URGN Urogen Pharma	2.7016 of 5 stars	$23.34 -3.2%	$34.13 +46.2%	+162.7%	$1.14B	$109.79M	N/A	200	News Coverage Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALIM) was last updated on 5/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alimera Sciences (ALIM) Competitors

ALIM vs. ABCL, PHAR, MLTX, URGN, and DBVT

How does Alimera Sciences compare to AbCellera Biologics?

Summary

How does Alimera Sciences compare to Pharming Group?

Summary

How does Alimera Sciences compare to MoonLake Immunotherapeutics?

Summary

How does Alimera Sciences compare to Urogen Pharma?

Summary

How does Alimera Sciences compare to DBV Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALIM vs. The Competition

Alimera Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alimera Sciences (ALIM) Competitors

ALIM vs. ABCL, PHAR, MLTX, URGN, and DBVT

How does Alimera Sciences compare to AbCellera Biologics?

Do insiders & institutionals believe in ALIM or ABCL?

Which has better valuation and earnings, ALIM or ABCL?

Does the media refer more to ALIM or ABCL?

Which has more volatility and risk, ALIM or ABCL?

Is ALIM or ABCL more profitable?

Do analysts rate ALIM or ABCL?

Summary

How does Alimera Sciences compare to Pharming Group?

Do insiders & institutionals believe in ALIM or PHAR?

Which has better valuation and earnings, ALIM or PHAR?

Does the media refer more to ALIM or PHAR?

Which has more volatility and risk, ALIM or PHAR?

Is ALIM or PHAR more profitable?

Do analysts rate ALIM or PHAR?

Summary

How does Alimera Sciences compare to MoonLake Immunotherapeutics?

Which has more risk and volatility, MLTX or ALIM?

Which has stronger valuation & earnings, MLTX or ALIM?

Does the media refer more to MLTX or ALIM?

Do analysts recommend MLTX or ALIM?

Do institutionals & insiders believe in MLTX or ALIM?

Is MLTX or ALIM more profitable?

Summary

How does Alimera Sciences compare to Urogen Pharma?

Do analysts rate ALIM or URGN?

Which has more risk and volatility, ALIM or URGN?

Do insiders and institutionals have more ownership in ALIM or URGN?

Is ALIM or URGN more profitable?

Which has preferable valuation & earnings, ALIM or URGN?

Does the media prefer ALIM or URGN?

Summary

How does Alimera Sciences compare to DBV Technologies?

Do insiders and institutionals have more ownership in ALIM or DBVT?

Does the media prefer ALIM or DBVT?

Which has more risk and volatility, ALIM or DBVT?

Do analysts rate ALIM or DBVT?

Which has preferable valuation & earnings, ALIM or DBVT?

Is ALIM or DBVT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALIM vs. The Competition

Alimera Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools